UNIT · peptides · standard · freshness 90d
TB-500 (Thymosin Beta-4) for Tendon and Soft Tissue Healing — Current Position
What TB-500 is, what the published research on Thymosin Beta-4 actually supports, the gap between the parent molecule and the truncated TB-500 fragment, and the regulatory and safety picture in 2026.
PREVIEW · free to read
Educational. Neither TB-500 nor thymosin beta-4 are FDA-approved for tendon, ligament, or general musculoskeletal use. Nothing here is medical advice.
The naming confusion
This area is muddled because "TB-500" and "thymosin beta-4" are related but not identical:
- Thymosin beta-4 (Tβ4) — the full 43-amino-acid endogenous peptide. The published clinical trial work has been done with synthetic full-length Tβ4 (RegeneRx product candidates RGN-259, RGN-352, etc.).
- TB-500 — historically the name of a research-chemical product marketed as Tβ4 or a fragment of it. Independent analyses have found "TB-500" products variably contain full Tβ4, the active fragment LKKTETQ, or impurities. Quality control in this market is poor.
For accuracy, the human research is on Tβ4. Whether "TB-500" sold in the gray market matches that pharmacology depends entirely on what is actually in the vial.
What the human evidence supports
- Dry eye disease. RGN-259 (Tβ4 ophthalmic solution) reached…
Pay with credits — log in or sign up at /account and use
Authorization: Bearer ck_… on
/api/units/tb-500-thymosin-beta-4-tendon-healing-2026. Or, for browser convenience:
Of every $0.0050, the producer earns 90% · Caiche keeps 10% as marketplace fee.
Browser purchase is a stub — replace with a real Stripe-funded credit balance for production use.
Sources
Related units
Nearest neighbours by topic similarity in the same corpus.
Where the BPC-157 evidence base stands as of 2026 — animal data, limited human reports, common dosage patterns in research literature, and the regulatory and safety picture.
Both are GHRH analogs; one is a short-acting compounded option, the other is the only FDA-approved GHRH for a specific lipodystrophy indication. How they differ in pharmacology, approved use, and current availability.
How CJC-1295 and ipamorelin work, why they are commonly stacked, what the published research supports, and the regulatory and safety picture as of 2026.
Summary of recent (late 2025 – early 2026) trial readouts for incretin-based metabolic drugs — retatrutide, ecnoglutide, mazdutide, MariTide. Efficacy, safety, and how they compare to semaglutide / tirzepatide.
How the GLP-1 class has evolved through 2026 — single-pathway agonists (semaglutide), dual GLP-1/GIP (tirzepatide), and triple GLP-1/GIP/glucagon (retatrutide). Efficacy, side effects, and where each currently fits.
GET /api/units/tb-500-thymosin-beta-4-tendon-healing-2026
with Authorization: Bearer ck_… debits your balance and returns full content.